BioNexus Gene Lab Corp BGLC revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BioNexus Gene Lab Corp reported revenue across 6 geographies; the largest, MY, was $5.83M, 78.5% of the filed sum (-21.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- MY$5.83M78.5%-21.8% yoy
- MV$681K9.2%-10.6% yoy
- LK$453K6.1%-1.4% yoy
- Singapore$241K3.2%-57.9% yoy
- ID$115K1.5%-16.9% yoy
- BD$106K1.4%-13.8% yoy
Members sum to the consolidated $7.42M for this period.
- MY$22.8K100.0%-98.7% yoy
- MV$00.0%-100.0% yoy
- LK$00.0%-100.0% yoy
- Singapore$00.0%-100.0% yoy
- BAM$00.0%-100.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.